Pay in 4 interest-free payments of $5.72 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
11 Future Perspectives 11.1 Monotherapy Given the modest weight loss delivered by SGLT2 inhibitors, it is not likely that they will be successful as monotherapies for obesity
Value Health 17(4):462470
These findings largely align with whats been seen with tirzepatide and other GLP-1based medications, including small risks of pancreatitis and gallbladder issues, dose-related gastrointestinal side effects, and discontinuation due to tolerability
Our team navigates this on your behalf and will always be honest about what we can and cannot offer
US$ 23.79
US$ 21.72
US$ 29.01
US$ 27.54
US$ 23.22
US$ 29.75
